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Summary and future perspectives
Summary
This thesis reveals additional insights in the functiolral behavior of P-glycoprotein
in the human blood brain barrier, in P--elycoproteirr expression and frurction in
animal mcldels, and in P-glycoprotein expression in the human blood-testis barrier
and in testicular tumors. The blood-brain barrier is a major obstacle for drug
delivery to the brain. Many anti-cancer, anti-epileptic, or anti-HlV drugs reach, due
to the bloo-brain barrier function, relatively low brain concentrations, resulting in
poor efhcacy of these drugs in the brain. F-or that reason the brain is often
considered a sanctuary, harboring unaffected canceí cells during chernotherapy.
lncreasing drug delivery to the brain inay lead to better treatment results, e.g. of
brain metastases. One ntajor target to increase drug levels in the brain is the efflLrx
purnp P-glycoproteirr, which has been demonstrated to efflux many substrates Íiom
the brain to the blood. Results of studies in prrt ients.  using inhibi tors of P-
glycoprotein function such as cyclosporin A and PSC 833 showed that treatment
with the se drugs círn iead to neurological side effècts. Especiaily organ
transplantation patients using high doses of cyclosporin A as irntnunosltppressant,
are susceptible to develop tremors and epileptic insults. For that reason it is
hypothesized that inhibition of P-glycoprotein firnction mav lead to increased
levels o1' cytotoxic P-glycoprotein substrates to the brain. Furthermore it has
already been shorvlr in anirnals tirat positron ernission tornography (PET) lvith
lilC]veraparnil oÍïèrs the opportunit.v to measure P-glycoprotein firnction in vivo.
ln Chapter 2 the literature about the blood-brain barrier is revieu'ed. The blood-
brain barrier cot.tsists of capillary endothelral cells, closely connected together with
tight jtrnctions, and iacking Íènestrations. These physicochernical properties
rvi thhold the eutrance oÍ ' large and polar rnolecules in the brain. Lipophi l ic or srnal l
tnolecules can cnter the: brain hy passive cli1 ÍLrsion, r,vhich is dependent on their
lipid solubilitv. expressed as octanol r,vater partition coefïlcient (log Pn,',,).
However, uranY drugs leach iower brain concentraticlns than predictecl b,v their log
P,,,,u and therefore crtirer fàctors ii lso kl'rn the blood-brain barrier. Ít has beerr
showlr that a large categor-v of these clrugs are substrate for active, ATP depencient,
drr"rg eí ux pulrps. P-glycoprotein and the rriultidrr;g resistance associated pfotcin
fnntill ' {N,lRP) are well kuor'vt.r c111ux pnrnps, but, according to current knorvledge.
l l )
the wide branched family of human efflux pumps consists of 48 members
(http://nutrigene.4t.com/humanabc.htrn). P-glycoprotein has a broad substrate
specificity and is expressed in rnany rnulti-drug resistant (MDR) tumors. P-
glycoprotein plays an important role in homeostatic organs such as liver and
kidney. In the blood-brain barier, P-glycoprotein actively transports harmful
lipophilic agents Íiom the brain to the blood, contributing to brain homeostasis,
which is necessary for a stable micro-environment, enabling proper brain function.
P-glycoprotein function can competitively be inhibited by various P-glycoprotein
substrates, such as the irnmunosuppressant cyclosporin A. This P-glycoprotein
funct ion can be visual ized in vivo with PET and IrrC]verapamil .
ln Chapter 3 PET antl frrC]verapamil were used (1) to study whether the
distribution volume is useful Íbr quantification of (labeled) P-glycoprotein
substrate kinetics over the blood-brain barrier and (2) to study how brain
distribution volume is affected by P-glycoprotein modulation. We measured the
kinet ics of the P-glycoprotein substrate ["Clverapamil  {0.1 rng'kgt in rat brains
using PET and afierial blood sarnpling. Cyclosporin A was used as P-glycoprotein
modulator. ["C]Verapamil kinetics was very well described by distribution
volume, computed by non-compartmental Logan analysis. Logan analysis resulted
in exceller-rt fits of dynarnic PET data, revealing the reversible behavior of
["C]veraparnil and its associated istribution volume. The distribution volume in
unmodulated rats was 0.65 ml/ml + 0.23 (mean + sd). After modulation with i0,
15,25,35 and 50 rng/kg cyclosporin A, distr ibut ion volume increased to 0.82 t
0 .06 ,  1 .04  +  0 .20 ,  2 .85  +  0 .51 ,  2 .91  +  0 .64  and 3 .17  +  1 .23  ml / rn l  respec t ive ly .
f"C]Veraparnil kinetics was saturable at modulation levels above 25 rng/kg
cyclosporin A. The data fittedwell by a 4-parameter Hill-plot 1r::0.101. Frorrr this
study we conclude that the distribution volume of ["C]verapamil is a valid and
potent tool to measure the kinetics of (labeled) P-glycoprotein substrates in vivo at
the blood-brain barrier. Brain distribution volume of []rC]verapamil increases
dose-dependently b  P-glycoprotein modulatiou.
The quantitative description as developed in the previous chapter rvas applied to
human beings. In Chapter 4 is described whether the immunosuppressive P-
glycoprotein substrates cyclosporin A or tacrolimus can modulate P-glycoprotein
function in tlie human blood-brain barrier. Lung transplantation patients (n:8)
r.rsing the highest clinical applicable dosages of cyclosporin A or tacrolirnus as
immunosuppressant. 'were compared with healthy volunteers (n:10).  Al l
individuals underwent a dynanric IrrC']verapamil PET procedure. Tissue and
plasma kinet ics of I rrC]veraparni l  were used to calculate the distr ibut ion volume in
grey and white matter and the influx constant K1 by means oí'Logan analysis. With
Logan analysis lve demonstrated excellerrt Ílts of plasrna verslls brain tissue time-
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distribution volume of ["C]verapamil in the gray matter as well as in white and
gray matter together were higher (21 % and 31 0Á, respectively) in patients than in
volunteers (p:0.03), whereas the influx constant K1 was not affected. Therefore it
was concluded that P-glycoprotein function indeed can be modulated at the level of
the human blood-brain barrier. The C3435T single nucleotide polymorphism on the
MDR1 gene revealed that the CC genotype was for all individuals correlated to a
lower distribution volume of IrrC]verapamil than the CT and the TT genotype
(p:0.01).
Chapter 5 describes a human small-cell lung cancer xenograft model in rat brains.
In this study the question was posed whether newly formed vessels do express P-
glycoprotein, and whether such xenografts do behave different from normal brain
tissue with respect to uptake of the P-glycoprotein substrate ["C]verapamil. P-
glycoprotein was equally expressed in the capillary endothelial cells of normal
brain tissue and the xenograft. P-glycoprotein was not expressed on glial cells. No
differences were observed between vessel density in normal brain tissue and the
xenograft. Without cyclosporin A, uptake of IrrC]verapamil rn the xenograft was
10 times higher than in normal brain tissue (p-0.0a). Cyclosporin A increased
[r]C]verapamil uptake in a dose dependent manner in striatum and cortex (p:0.0a
and p:0.015). Uptake in cortex and striatum at 50 mgikg cyclosporin A equals the
maximum uptake of IrrC]verapamil in the tumor which was already reached at 10
mg/kg cyclosporin A (p:0.05). This means that five times less cyclosporin A was
required to increase ["C]verapamil uptake in GLC4 xenografts to the same level as
maximal uptake in normal brain tissue. P-glycoprotein is expressed in newly
formed rat vessels, growing into cerebral human small cell lung cancer cell
suspension xenografts. The maximal uptake in the xenograft was reached at lower
cyclosporin A dose than necessary for maximal ["C]verapamil uptake in the
nomal brain indicating a higher effect on xenografts.
Chapter 6 describes the study performed to elucidate whether the use of the P-
glycoprotein substrate IrrC]carvedilol is of additional value for functional P-
glycoprotein imaging with PET. Ideally, for the purpose of brain imaging, tracers
should have a lipid solubility, expressed as octanol water partition coefficient (log
Po7*) between 0.9 and 2.5.The anti-hypeÍensive B-receptor antagonist carvedilol is
aP-glycoprotein substrate with a log Pn7* :2.0.I t  can be labeled with Ir 'C1. C. l l
l ine experiments in the parental cell l ine GLC4, and the MDR1 transfected cell l ine
GlC4/P-glycoprotein and the MRPl overexpressing cell l ine GLC4/Adr showed
that IrrC]carvedilol uptake increased 3-fold in the P-glycoprotein expressing cell
l ine after pretreatment with cyclosporin A. The parental cell l ine and the MRPI
overexpressing cell l ine were not afïected by cyclosporin A, nor by the MRPI
inhibitor MK571. Biodistribution studies in rats showed that IrrC]carvedilol uptake
in the brain was increased 5-fold by cyclosporin A. Ir]C]Carveditol uptake in other
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oïgalrs was not aÍ1ècted by cyclosporin A. Autoradiopgraphy studies revealed that
IrrC]carvedilol was hornogeneously distributed over tlre brain arrd that pretreatment
u'ith cyclosporin A irrcreased [1rC']catvedilol uptake by maxirnal 7-fold. Logan
ar-ralysis of brain kinetics of ["C]carvcdilol, obtained Ír'orn in vivo PET
experirnents resulted in cxcel lent f - i ts,  reveal i rrg that ["C]carvedi lol  is not t rapped
i r r  t l re  b ra in .  Bra in  d is t r ibu t io r r  ro l r r rne  o l ' l r r t ' l ca r rcd i lo l  shorved a dose-depcnden{
increase of maximal 3-fbld after cyclospolir-r A pretreatlnent. Above doses of l5
mg/kg there was no change in distr ibut ion volurne. Compared to [rrC]verapanri l
experiments, described in chapter ?, less cyclosporin A was needed to reaclr
rnax i rna l  d is t r ihu t ion  vo lu rne .  suggest ing  tha t  IL t  l ca l red i lo l  i s  a  Inore  sens i t i re
tool to measurc P-glycoprotein funct ion in vivo than IrrC]vcraparni l .
I rrC]can edi lol  is a prornisirrg tracer '10 opt irnize P-glycoprotein maging with PET.
ln Chapter 7 lt has been shorvlr that expression of P-glycoprotein decreases early
aÍter brain inadiation. To elucidate whether radiotherapy reduces P-glycoprotein
expressior.r and function, right hemispheres ol'rat brains were irradiated with single
doses o1'2, 5,  10, 15. and 25 Gy Íbl lowed by l0 rng/kg cyclosporin A after 5 days,
or with a single dose of 15 Gy Íbllowed after 5 days by difÍèrent doses of
cyclosporin A (10,5, arrd 20 mg/kg),  or f iact ionated irradiat ion (4 x 5 Gy) and(10
mg/kg) fbllowed by cyclosporin A alier 5 days. Cyclosporin A u'as administered iv
30 min pr ior to IrrC]carvcdi lol  in iect ion. Addit ional ly 4 gloups o1'rats wele
irradiated n'ith 25 G1, and alter 10, 15, 20, and 25 days. These rats were sacrillced.
and their brains \\rere removed. Irradration resulted in a dose- dependent increase
on day 5 o1' [ 'C]calvediiol uptakc up to maxinal 20oÁ o1' the non-irradiated
hernisphere. ln addit iou. cyclosporin A irrcrcirsr-s [" t ' ]carv. 'd i lo l  uptakc dose-
clependent ly,  in both hernispheres, but I rrC]carvedi lol  uptake u'as higher (p<0.001)
in the irradiated hernisphere. Fractionated irradiation induced thc sarne increas.' irr
l "C]carvedi lol  uptake at the sanre biological  eí fect ive dose as single dose
irradialion. P-glycoprotein expression decreases betrveen l0 and 20 day alter single
dose irradiation with 25 Gy, and incrcases afterw-ards to the same ol higher ler,els
as befbre irradiation. Flom lhese erperirrrents it carr be concluded that irradiation of
the rat brain induccs a reduct ion of P-glycoplotciu crprcssion and funct ion. I f  this
applies 1o lruman beings, i1 can be hvpothesized that radiolherapv, u,hich is
l iccluerrt l l 'appl ieci  to hurnans rvi th brain metastases. could be useÍ ir l  to increase
del iver l  ol 'chernotherapy to the brain.
For that reasou in Chapter 8 it is c'letermined in patients rvhether radiothelapy
increases clel ivcr l .ol ' [ "C] l 'eraparni l  as r .neasured rvi th distr ibut ion volut le.  I rr  this
st i l l  ongoing study (non) smal l  cel l  lung cancer pat ients with brairr  nretastases,
trealed rvi th pal l iat ive w.hole brair-r  racl iotherapy (5 x,1 ( i1 ' )  undergo a
["C]r,eraparrril PET procedure belbre and alter ladiothelapy. Re-uirxs of interest
arc clel lued on l)  braiu nietastases, 1) nclrmal brain contralateral  o1' the metastascs.
l l 8
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and 3) a large part of nonnal brain tissue. Frorn these regions ["C]verapamil
kinet ics in t issue are obtained. Durirrg the IrrC]veraparni l  scarr bloocl  samples are
collected to determine ["C]verapamil kinetics ir-r plasma. Tissue and plasma
kinetics are used to calculate the distribution volume and the inf'lux constant K1 of
["C]veraparnil in the difÍerent regions. Until now 15 patients entered the study, of
which 7 had sr-rfÏlcient condition to undergo the second scan after radiotherapy. All
patients were treated with dexarnethasone, and if epileptic seizures were present
also lv i th fènytoin. Scans were rnade 14.7 + 9.3 days (mean + sd) before and 14.7 +
5.8 clays after the Írrst radiotherapy session. BeÍbre radiotherapy rnean distribution
volulne 1+ sd) in the metastasis is 1.04 + 0.33 and contralateral of the metastasis
0.60 + 0.15 (p:0.03).  The K1 was not signi Í icanrly di f lèrent (p:0.06).  After
radiotherapy mean distribution volume and K1 1+ sd) in the metastases were both
decreased (p:0.04 and 0.0 I ) in contrast to the contralateral region where
distr ibut ion volurne and K1 were not aÍïècted (p-0.06).  Since the distr ibut ion
volume is l inearly related to K1, changes in P-glycoprotein f lnct ion in the
rretastasis, induced by irradiation can not be estirnated. Radiotherapy (5 x 4 Gy)
does not increase ["C]vernparnil delivery to the hurnan brain within two weeks
after radiotherapy. Horvever,  the ini t ia l ly higlrcr I rrC]verapamil  del ivery to brain
rneteistases is reduced after radiotherapy which calt potentially be explained by
reduced inÍlr"rx. Therefbre, fttture studies should be perÍbrrned to elucidate whether
radiotherapy shoLrld precede chemotherapy or reverse.
Chapter 9
The Íbnction of the blood-testis barrier is to protect gernr cells against harrnful
inf-luences, thus also impeding tlre delivery of chemotherapeutic drr,rgs to tlre testis.
In this sense, the blood-test is barr ier shares ur lnv propert ies rvi th the blood-brain
barr ier,  lvhich protects the brain. In this chapter the architecture of the blood-test is
barrier is described, and conrpared to the blood-brain barrier. The bloocl-testis
barrier is a tlrreefbld barrier. Firstly a physico-cherrical barrier, consisting of
cont inuous capi l lar ies, Sertol i -cel ls in the tubular rval l ,  connected together with
narrow t ight jLrnct ions, and a m1'oid cel l  layer around the semini Íèrous tubule.
Secondly an eÍïlux purnp barrier that contains P-glycoprotein in the luminal
capi l lary endothel iurn and or. t  the nryoid cel l  Iayer,  arrd Mult idrug-Resistance
associated Protein I  (MRPI) locatecl  basolateral ly on Sertol i -cel ls.  1-hirdly the
bloocl- test is barr ier consists of an i rnrnunolngical  barr ier,  consist ing of F'as- l igand
on Sertol i -cel ls.  I f  the results on imaging and moclulat ion of P-glycoprotein i  thc
brain also applv to t l re test is,  inhibi t ion of P-glycoprotein funct ion potent ial ly
of lèrs the opporluni ty to increase the del iverv of cytotoxic drugs to the test is.  [n the
l l turc r , isual izat ion of the blood-test is barr ier l lnct ion rnav also be helotrr l  to
l t 9
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determine patient groups, in which testis conservation is safe or to select drugs that
are less harmful for fertility.
Chapter 10 The precise localization of P-glycoprotein and MRPI in the testis and
in primary testicular tumors is largely unknown. We studied the localization of P-
glycoprotein and MRPI in the blood-testis barrier in normal testicular tissue and in
primary seminomas, non-seminomas, and testicular lymphomas. In normal
testicular tissue P-glycoprotein was strongly expressed on myoid cells surrounding
the seminiferous tubule, and on Leydig cells and capillary endothelium, but not on
Sertoli cells. MRPI was expressed on Sertoli cells and Leydig cells. Seminomas
and non-seminomas expressed P-glycoprotein or MRPI or both, while lymphomas
strongly expressed P-glycoprotein but no or weakly MRPI. Newly formed vessels
expressed P-glycoprotein but no MRPI. This was regardless of tumor type. This
study illustrates that P-glycoprotein and MRPI are expressed in different cell
layers of the normal testis, which suggests optimal protection of spermatogenesis.
The expression of efflux pumps on gerïn cell tumors may at least partly explain the
resistance of these tumors to P-glycoprotein and MRPI substrates. Both in germ
cell tumors and in testicular lymphomas P-glycoprotein expression in newly
formed vessels may also contribute to chemoresistance. These findings are in favor
of the common practice to remove the affected in case of primary germ cell tumors
and testicular lymphomas, irrespective whether the patient already underwent
chemotherapy.
Future perspectives
The studies described in this thesis, have provided additional insight in the
functional nature of P-glycoprotein in the human blood-brain barrier. From these
studies it has become clear that if brain metastases are macroscopically visible, the
drug resistance of the metastasis is not solely due to P-glycoprotein function in the
blood-brain barrier but also to several other resistance mechanisms present in the
tumor. However, microscopic metastases may still be dependent on the normal
blood*brain barrier. Therefore, oncology research on P-glycoprotein function in the
blood-brain barrier should be directed particularly to the normal blood-brain
barrier. [t 'C]verapamil or [rrC]carvedilol PET can be used as a potent tool to
determine the capacity of new P-glycoprotein inhibitors, which are currently being
developed. Furthermore, if such P-glycoprotein inhibitors are available for clinical
applications they should primarily be applied as prophylactic co-treatment with
chemotherapy to patients with tumors that metastasize easily to the brain. Future
PET studies in patients can be helpful to determine whether patients are eligible for
co-treatment with a P-glycoprotein inhibitor. So far, no potent non-toxic inhibitor













































































glycoprotein inhibi tors,  such as ONT-093, LY335919, GFl209l8, and XR9576 are
currently tested in early clinical trials r2e,:0s'107'3llr.3le.
Many patients with other brain diseases, such as epilepsy or neuronal HIV do not
respond to brain drugs r5". lt has been suggested in rats and humans that p-
glycoprotein in the blood-brain barrier is involved in this resistance i83'2ó'1.
Knowledge obtained in this thesis could also be translated to these patient groups
to study whether inhibition of P-glycoprotein function in the blood-brain barrier is
useful to increase drug delivery the brain. For instance patients with epilepsy,
refractory to anti-epileptic drugs could be treated with a new, non-toxic P-
glycoprotein inhibitor. Clinical therapy outcome, such as frequency of seizures can
easily be compared to brain pharmacokinetics of IrtC]verapamil measured with
PET. Another field off interest is functional imaging of genetic differences. It is
known that the MDRI gene, encoding for P-glycoprotein exhibits several single
nucleotide polymorphisms, some of which result in different transport capabilities.
A recent study suggests that the single nucleotide polymorphism C3435T on exon
26 of the MDR1 gene, coding for P-glycoprotein, may induce phenotypes with
different sensitivity to anti-epileptics rre. Patients resistant to anti-epileptic drugs
were more likely to have the CC genotype. Functional imaging of P-glycoprotein
may largely strengthen the conclusions based on the observations in this study.
Based on the results of the studies described in this thesis, it is likely that
functionally different phenotypes as a consequence of different genotypes can be
detected by means of IrrC]verapamil or IrrC]carvedilol PET. On the other hand,
inconceivable interindividual variances of functional measurements may in some
cases be explained by so far unknown differences in genotype.
It is still a matter of debate whether patients with brain metastases can benefit from
concurrent radiotherapy and chemotherapy. In our study in rats, treated with
irradiation alone, a reduction of P-glycoprotein expression and function was found.
This finding justifies studies in patients undergoing radiotherapy, to determine the
effects of radiotherapy on brain delivery of P-glycoprotein substrates. Our
preliminary study in patients showed after l4 days no effects in normalbrain, and a
decreased elivery of IrrC]verapamil to brain metastases. Although this study is
ongoing, it is questionable whether macroscopic brain metastases benefit more
from chemotherapy Íbllowing radiotherapy than from radiotherapy or
chemotherapy alone. However, other radiation schedules and doses may be subject
of future studies to increase drug delivery to the brain.
At present, P-glycoprotein is frequently studied in drug delivery questions. It is
currently well krown that at least 48 transporters from the ATP binding cassette
family contribute to transmembrane transport. Many of these transporters are
expressed in the blood-brain barrier, where they are involved in the protection of
the brain. However, little is known about the function of these transoorters. Manv
l 3 t
of these transporters share their substrates. In addition they exhibit different
mechanisms of action. lt is therefore reasonable that inhibition of one or two of
these pumps will only result in a very limited effect on drug delivery to the brain.
For that reason future studies should not only investigate P-glycoprotein but also
other transporters. lnsight in the function these transporters may potentially lead to
possibilities to increase drug delivery to sanctuary sites such as the brain and the
testis. Additionally, it may also provide knowledge which may lead to increase the
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